Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.

Ascierto PA, Fox B, Urba W, et al. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer. 2020;8:e000878. doi: 10.1136/jitc-2020-000878

Since the online publication of this article, the authors have noticed the following errors:

1) The following authors were missing the middle initial in their name; Bernard A Fox, Walter J Urba, Julie R Brahmer, Daniel S Chen, Tanja D de Gruijl, F Stephen Hodi Jr, Howard L Kaufman, Michael T Lotze, Kim M Margolin, Francesco M Marincola. The author name Jon M Wigginton was also spelt incorrectly as Jon M Wiggington. The author list is shown below and has been updated in the article.

Paolo Antonio Ascierto,1 Bernard A Fox,2 Walter J Urba,2 Ana Carrizosa Anderson,3 Michael B Atkins,4 Ernest C Borden,5 Julie R Brahmer,6 Lisa H Butterfield,7 Alessandra Cesano,8 Daniel S Chen,9 Tanja D de Gruijl,10 Robert O Dillman,11 Charles G Drake,12 Leisha A Emens,13 Thomas F Gajewski,14 James L Gulley,15 F Stephen Hodi Jr,16 Patrick Hwu,17 David Kaufman,18 Howard L Kaufman,19 Michael T Lotze,20 Douglas G McNeel,21 Kim A Margolin,22 Francesco M Marincola,23 Michael J Mastrangelo,24 Marcela V Maus,25 David R Parkinson,26 Pedro J Romero,27 Paul M Sondel,28 Stefani Spranger,29 Mario Sznol,30 George J Weiner,31 Jon M Wigginton,32 Jeffrey S Weber33

2) Affiliations 1, 2, 3, 4, 5, 11, 14, 15, 16, 20, 21, 22, 26, 28 were incorrect and affiliations 8, 32, 34 have been removed. The updated affiliation list is shown below and has been updated in the article.

1Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Naples, Italy

2Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA

3Harvard Medical School, Boston, Massachusetts, USA

4Georgetown Lombardi Comprehensive Cancer Center, Washington DC, USA

5University of Wisconsin Clinical Cancer Center, Madison, Wisconsin, USA

6Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA

7Research, Parker Institute for Cancer Immunotherapy, San Francisco, California, USA

8ESSA Pharma Inc, Redwood City, California, USA

9IGM Biosciences Inc, Mountain View, California, USA

10Medical Oncology - Amsterdam University Medical Centers, Vrije Universiteit-Cancer Center Amsterdam, Amsterdam, The Netherlands

11AIVITA Biomedical, Inc, Irvine, California, USA

12Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York, USA

13UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA

14Pathology and Medicine, Immunology and Cancer Program, University of Chicago, Chicago, Illinois, USA

15National Cancer Institute, Bethesda, Maryland, USA

16Dana Farber Cancer Institute, Boston, Massachusetts, USA

17University of Texas MD Anderson Cancer Center, Houston, Texas, USA

18Bill & Melinda Gates Medical Research Institute, Cambridge, Massachusetts, USA

19Immuneering Corp New York, New York, New York, USA

20University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

21Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA

22Medical Oncology, City of Hope National Medical Center, Duarte, California, USA

23Refuge Biotechnologies, Menlo Park, California, USA

24Thomas Jefferson Medical College, Philadelphia, Pennsylvania, USA

25Massachusetts General Hospital Cancer Center, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA

26ESSA Pharma Inc, Palo Alto, California, USA

27Oncology, University of Lausanne, Lausanne, VD, Switzerland

28Pediatrics, University of Wisconsin Madison, Madison, Wisconsin, USA

29Massachusetts Institute of Technology Koch Institute for Integrative Cancer Research, Cambridge, Massachusetts, USA

30Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA

31Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, Iowa, USA

32MacroGenics Inc, Rockville, Maryland, USA

33Laura and Isaac Perlmutter Comprehensive Cancer Center, NYU Langone Medical Center, New York, New York, USA

3) In the main text,

The sentence ‘The hypoxia and profound inflammatory response associated with the pneumonitis observed with the severe acute respiratory virus coronavirus-2 SARS-COV-2 virus…’ now reads ‘The hypoxia and profound inflammatory response associated with the pneumonitis observed with the SARS-CoV-2 virus…’

The sentence ‘One possibility is to encourage the use of IL-6 or IL-6-receptor (IL-6R) blocking antibodies like tocilizumab (Actemra, Roche-Genentech), sarilumab (Kevzara, Regeneron) and siltuximab (Sylvant, EUSA Pharma)…’ now reads ‘One possibility is to encourage the use of IL-6 or IL-6-receptor (IL-6R) blocking antibodies like tocilizumab (ActemraTM, Roche-Genentech), sarilumab (KevzaraTM, Regeneron) and siltuximab (SylvantTM, EUSA Pharma)…’

The sentence ‘…including tocilizumab and sarilumab for use on a compassionate basis to critically ill hospitalized COVID-19-infected patients during this extraordinary situation’ now reads ‘…including tocilizumab and sarilumab for use on a compassionate basis to critically ill hospitalized SARS-CoV-2-infected patients during this extraordinary situation’

4) To acknowledge medical writing support, the acknowledgment section has been updated to read:

‘The authors thank the clinicians working tirelessly on the frontlines of the COVID-19 pandemic. The authors also acknowledge SITC staff for their contributions including Sam Million Weaver, PhD for medical writing and editorial support and Angela Kilbert for project management and assistance. Additionally, the authors wish to thank the society for supporting the manuscript development.’

5) In the competing interests section:

Bristol-Myers Squibb was spelt incorrectly as ‘Bristol-Myer Squibb’ and ‘Bristol-Myers-Squibb’

The initials for authors BF, JB, ACA, DC, TdG. HK, ML, FM, KM now read BAF, JRB, AC, DSC, TDG, HLK, MTL, FMM, KAM